甲磺酸阿帕替尼联合肝动脉栓塞化疗治疗中晚期原发性肝癌的效果
|
摘要
目的观察甲磺酸阿帕替尼联合肝动脉栓塞化疗(TACE)治疗中晚期原发性肝癌的效果和安全性。方法选择2015年1月～2016年8月武汉大学人民医院肿瘤科进行治疗的50例中晚期原发性肝癌患者作为研究对象。通过回顾性分析,将患者分为联合组和对照组,每组25例。联合组患者行TACE后,序贯口服甲磺酸阿帕替尼治疗,对照组患者仅接受TACE治疗。比较两组患者的临床缓解率、生存时间和不良反应发生率。结果联合组的临床缓解率明显高于对照组(P <0.05);联合组的总生存时间长于对照组(P <0.05);两组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论甲磺酸阿帕替尼联合TACE在中晚期原发性肝癌患者的治疗中具有改善临床效果,延长患者生存时间,安全性良好的优点。
Objective To observe the efficacy and safety of Apatinib Mesylate combined with hepatic arterial chemoembolization(TACE) in the treatment of advanced primary liver cancer. Methods From January 2015 to August 2016, 50 patients with advanced primary liver cancer treated in the Department of Oncology, Renmin Hospital of Wuhan University were selected as subjects. By retrospective analysis, patients were divided into combined group and control group, with 25 cases in each group. Patients in the combination group received TACE followed by sequential oral administration of Apatinib Mesylate, while patients in the control group received TACE alone. The clinical remission rate,survival time and incidence of adverse reactions were compared between the two groups. Results The clinical remission rate of the combined group was significantly higher than that of the control group(P < 0.05). The total survival time of the combined group was longer than that of the control group(P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05). Conclusion Apatinib Mesylate combined with TACE has the advantages of improving clinical effect, prolonging survival time and good safety in the treatment of patients with advanced primary liver cancer.
Objective To observe the efficacy and safety of Apatinib Mesylate combined with hepatic arterial chemoembolization(TACE) in the treatment of advanced primary liver cancer. Methods From January 2015 to August 2016, 50 patients with advanced primary liver cancer treated in the Department of Oncology, Renmin Hospital of Wuhan University were selected as subjects. By retrospective analysis, patients were divided into combined group and control group, with 25 cases in each group. Patients in the combination group received TACE followed by sequential oral administration of Apatinib Mesylate, while patients in the control group received TACE alone. The clinical remission rate,survival time and incidence of adverse reactions were compared between the two groups. Results The clinical remission rate of the combined group was significantly higher than that of the control group(P < 0.05). The total survival time of the combined group was longer than that of the control group(P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05). Conclusion Apatinib Mesylate combined with TACE has the advantages of improving clinical effect, prolonging survival time and good safety in the treatment of patients with advanced primary liver cancer.
引文
[1]王永刚,吴金术,蒋波,等.解剖性肝切除治疗肝硬化原发性肝癌近期疗效分析[J].湖南师范大学学报:医学版,2013,10(4):78-80.
[2]沈强,蓝瑚,王懿儒,等.碘化油.顺铂肝动脉栓塞术治疗不能切除的中晚期原发性肝癌的临床研究[J].昆明医学院学报,1990(2):51.
[3]冯久桓,秦叔逵,王琳,等.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017,22(4):345-356.
[4]秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015(9):841-847.
[5]李旭,张翠翠,谭红叶,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016(2):91-93.
[6]王晓蕊,汪旭,史业辉,等.阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察[J].中国肿瘤临床,2017,44(15):769-772.
[7]中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,20(11):929-946.
[8]丁婕,戴旭,孟宪运,等.实体瘤评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.
[9]王珂,汪爱勤,尹文,等.原发性肝癌的治疗进展[J].山东医药,2014,54(43):88-90.
[10]祝普利,尹超,冯建龙,等.原发性肝癌综合治疗进展[J].临床肝胆病杂志,2015,31(6):965-968.
[11]李威满,郭欢庆.TACE联合甲磺酸阿帕替尼治疗中晚期肝癌的临床研究[J].肿瘤药学,2017,7(1):74-78.
[12] Jayson GC,Kerbel R,Ellis LM,et al. Antiangiogenic therapy in oncology:current status and future directions[J].Lancet,2016,18(3):321-323.
[13] Weis SM, Cheresh DA. Tumor angiogenesis:molecular pathways and therapeutic targets[J]. Nat Med,2011,17(11):1359-1370.
[14]来炳岩,李芬.CT与B超在原发性肝癌首诊中的应用价值对比[J].中国CT和MRI杂志,2016,14(4):71-73.
[15]首志雄.原发性肝癌的多学科治疗进展[J].临床误诊误治,2013,26(5):103-106.
[16]陈丹,王凯冰,李加桩,等.原发性肝癌的抗血管生成靶向治疗现状与挑战[J].中国肿瘤,2017,26(3):203-209.
[17] Tian S,Quan H,Xie C,et al. YN968D1 is a novel and selective inhibi-tor of vascular endothelial growth factor receptor-2 tyrosine ki-nase with potent activity in vitro and in vivo[J]. Cancer Sci,2011,102(7):1374-1380.
[18] Lu W,Jin XL,Yang C,et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma:A single-center randomized controlled trial[J]. Cancer Biol Ther,2017,18(6):433-438.
[19]王宝泉,张岳林,聂春辉,等.阿帕替尼联合TACE治疗原发性肝癌疗效观察[J].心理医生,2017,23(3):64-66.
[20]王兰荣,王钖,曹旸,等.阿帕替尼联合动脉栓塞介入治疗肝癌的效果及对血管内皮生长因子和凋亡相关因子的影响[J].国际医药卫生导报,2017,23(7):1015-1017.
[2]沈强,蓝瑚,王懿儒,等.碘化油.顺铂肝动脉栓塞术治疗不能切除的中晚期原发性肝癌的临床研究[J].昆明医学院学报,1990(2):51.
[3]冯久桓,秦叔逵,王琳,等.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017,22(4):345-356.
[4]秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015(9):841-847.
[5]李旭,张翠翠,谭红叶,等.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果观察[J].中国生化药物杂志,2016(2):91-93.
[6]王晓蕊,汪旭,史业辉,等.阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察[J].中国肿瘤临床,2017,44(15):769-772.
[7]中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,20(11):929-946.
[8]丁婕,戴旭,孟宪运,等.实体瘤评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.
[9]王珂,汪爱勤,尹文,等.原发性肝癌的治疗进展[J].山东医药,2014,54(43):88-90.
[10]祝普利,尹超,冯建龙,等.原发性肝癌综合治疗进展[J].临床肝胆病杂志,2015,31(6):965-968.
[11]李威满,郭欢庆.TACE联合甲磺酸阿帕替尼治疗中晚期肝癌的临床研究[J].肿瘤药学,2017,7(1):74-78.
[12] Jayson GC,Kerbel R,Ellis LM,et al. Antiangiogenic therapy in oncology:current status and future directions[J].Lancet,2016,18(3):321-323.
[13] Weis SM, Cheresh DA. Tumor angiogenesis:molecular pathways and therapeutic targets[J]. Nat Med,2011,17(11):1359-1370.
[14]来炳岩,李芬.CT与B超在原发性肝癌首诊中的应用价值对比[J].中国CT和MRI杂志,2016,14(4):71-73.
[15]首志雄.原发性肝癌的多学科治疗进展[J].临床误诊误治,2013,26(5):103-106.
[16]陈丹,王凯冰,李加桩,等.原发性肝癌的抗血管生成靶向治疗现状与挑战[J].中国肿瘤,2017,26(3):203-209.
[17] Tian S,Quan H,Xie C,et al. YN968D1 is a novel and selective inhibi-tor of vascular endothelial growth factor receptor-2 tyrosine ki-nase with potent activity in vitro and in vivo[J]. Cancer Sci,2011,102(7):1374-1380.
[18] Lu W,Jin XL,Yang C,et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma:A single-center randomized controlled trial[J]. Cancer Biol Ther,2017,18(6):433-438.
[19]王宝泉,张岳林,聂春辉,等.阿帕替尼联合TACE治疗原发性肝癌疗效观察[J].心理医生,2017,23(3):64-66.
[20]王兰荣,王钖,曹旸,等.阿帕替尼联合动脉栓塞介入治疗肝癌的效果及对血管内皮生长因子和凋亡相关因子的影响[J].国际医药卫生导报,2017,23(7):1015-1017.